63 related articles for article (PubMed ID: 19317067)
21. Is there a correlation between tumor marker panel and tumor size and histopathology in well staged patients with borderline ovarian tumors?
Ayhan A; Guven S; Guven ES; Kucukali T
Acta Obstet Gynecol Scand; 2007; 86(4):484-90. PubMed ID: 17486473
[TBL] [Abstract][Full Text] [Related]
22. Spontaneous regression in recurrent epithelial ovarian cancer.
Fujiwaki R; Sawada K
Arch Gynecol Obstet; 2007 May; 275(5):389-91. PubMed ID: 17177031
[TBL] [Abstract][Full Text] [Related]
23. Pegylated liposomal doxorubicin in heavily pretreated epithelial ovarian cancer patients.
Gorumlu G; Kucukzeybek Y; Kemal-Gul M; Karaca B; Cosan-Terek M; Karabulut B; Sanli UA; Akman L; Ozsaran A; Dikmen Y; Uslu R
J BUON; 2008; 13(3):349-52. PubMed ID: 18979548
[TBL] [Abstract][Full Text] [Related]
24. [ZNF217 gene was detected in ovarian serous cystadenocarcinoma by fluorescence in situ hybridization].
Zhong M; Li J; Ding YQ; Song LL
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Dec; 23(6):665-7. PubMed ID: 17160949
[TBL] [Abstract][Full Text] [Related]
25. Low-grade ovarian cancer in an adolescent patient.
Parker LP; Ramirez PT; Broaddus R; Sightler S; Wolf JK
Gynecol Oncol; 2001 Jan; 80(1):104-6. PubMed ID: 11136580
[TBL] [Abstract][Full Text] [Related]
26. [Evaluation of radiotherapy for state I ovarian carcinoma].
Sheng X; Sun J; Zhou C
Zhonghua Zhong Liu Za Zhi; 1996 Jul; 18(4):314-6. PubMed ID: 9387332
[TBL] [Abstract][Full Text] [Related]
27. Ovarian papillary serous tumors of low malignant potential (serous borderline tumors). A long-term follow-up study, including patients with microinvasion, lymph node metastasis, and transformation to invasive serous carcinoma.
Kennedy AW; Hart WR
Cancer; 1996 Jul; 78(2):278-86. PubMed ID: 8674004
[TBL] [Abstract][Full Text] [Related]
28. Relapse after more than 20 years of follow-up for epithelial ovarian carcinoma.
Zylberberg B; Dormont D; Madelenat P; Daraï E
Obstet Gynecol; 2004 May; 103(5 Pt 2):1082-4. PubMed ID: 15121615
[TBL] [Abstract][Full Text] [Related]
29. AgNORs count correlates better than grading with the effect of chemotherapy in serous ovarian cancer.
Gottwald L; Danilewicz M; Suzin J; Wójcik-Krowiranda K; Bieńkiewicz A
Pol J Pathol; 2003; 54(4):239-42. PubMed ID: 14998291
[TBL] [Abstract][Full Text] [Related]
30. Foreign body reaction (gossypiboma) masking as recurrent ovarian cancer.
Deger RB; LiVolsi VA; Noumoff JS
Gynecol Oncol; 1995 Jan; 56(1):94-6. PubMed ID: 7821856
[TBL] [Abstract][Full Text] [Related]
31. [Application of multi-tumor markers in ovarian carcinoma].
Feng J; Qian H; Tian Y
Zhonghua Fu Chan Ke Za Zhi; 1998 May; 33(5):284-6. PubMed ID: 10682440
[TBL] [Abstract][Full Text] [Related]
32. Ovarian serous cystadenoma.
Tarlowska L; Sikorowa L; Piatkowski Z
Pol Med J; 1972; 11(2):368-79. PubMed ID: 5071524
[No Abstract] [Full Text] [Related]
33. Macrophage colony-stimulating factor enhances platelet recovery following cisplatin/carboplatin chemotherapy in ovarian cancer.
Suzuki M; Ohwada M; Aida I; Sato I; Tamada T
Gynecol Oncol; 1994 Jul; 54(1):23-6. PubMed ID: 8020834
[TBL] [Abstract][Full Text] [Related]
34. Second primary or recurrence? Comparative patterns of p53 and K-ras mutations suggest that serous borderline ovarian tumors and subsequent serous carcinomas are unrelated tumors.
Ortiz BH; Ailawadi M; Colitti C; Muto MG; Deavers M; Silva EG; Berkowitz RS; Mok SC; Gershenson DM
Cancer Res; 2001 Oct; 61(19):7264-7. PubMed ID: 11585764
[TBL] [Abstract][Full Text] [Related]
35. [Analysis of coagulative and fibrinolytic factors in peripheral and ovarian veins among ovarian cancer patients].
Ino Y
Nihon Gan Chiryo Gakkai Shi; 1987 Dec; 22(10):2417-26. PubMed ID: 3130448
[No Abstract] [Full Text] [Related]
36. CA125 nadir concentration is an independent predictor of tumor recurrence in patients with ovarian cancer: a population-based study.
van Altena AM; Kolwijck E; Spanjer MJ; Hendriks JC; Massuger LF; de Hullu JA
Gynecol Oncol; 2010 Nov; 119(2):265-9. PubMed ID: 20797777
[TBL] [Abstract][Full Text] [Related]
37. Tissue polypeptide specific antigen (TPS) and carbohydrate antigen 125 (CA-125) in the early prediction of recurrent ovarian cancer.
Yeh LS; Hung YC; Kao A; Lin CC; Lee CC
Anticancer Res; 2002; 22(6B):3669-71. PubMed ID: 12552974
[TBL] [Abstract][Full Text] [Related]
38. [Inhibin and ovarian cancer].
Burger HG; Baillie A; Drummond AE; Healy DL; Jobling T; Mamers P; Robertson DM; Susil B; Cahir N; Shen Y; Verity K; Fuller PJ; Groome NP; Findlay JK
Vopr Onkol; 1999; 45(4):369-73. PubMed ID: 10532093
[TBL] [Abstract][Full Text] [Related]
39. Serous ovarian carcinoma recurring as a heterologous carcinosarcoma.
Ferrandina G; Carbone A; Zannoni GF; Martinelli E; Testa AC; Gallotta V; De Ninno M; Scambia G
J Obstet Gynaecol Res; 2007 Feb; 33(1):95-9. PubMed ID: 17212675
[TBL] [Abstract][Full Text] [Related]
40. The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients.
Begum FD; Høgdall CK; Kjaer SK; Christensen L; Blaakaer J; Bock JE; Glud E; Høyer-Hansen G; Ring-Larsen H; Høgdall EV
Anticancer Res; 2004; 24(3b):1981-5. PubMed ID: 15274388
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
